Patents Represented by Attorney, Agent or Law Firm Rebecca R. Barrett
  • Patent number: 7671056
    Abstract: The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. The invention relates to compounds and pharmaceutically acceptable salts of formula (I?): wherein R1-R16, Ra, Rb, and n are set forth in the specification. The invention also relates to pharmaceutical compositions comprising compounds and pharmaceutically acceptable salts of formula (I?).
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: March 2, 2010
    Assignee: Wyeth LLC
    Inventors: Magda Asselin, George Theodore Grosu, Annmarie Louise Sabb, Wayne Everett Childers, Lisa Marie Havran, Zhongqi Shen, James Jacob Bicksler, Dan Chaekoo Chong
  • Patent number: 7179944
    Abstract: A process for the preparation of a compound of formula I, wherein R1 and R2 are ortho or para substituents, independently selected from the group consisting of hydrogen, hydroxyl, C1–C6 alkyl, C1–C6 alkoxy, C7–C9 aralkoxy, C2–C7 alkanoyloxy, C1–C6 alkylmercapto, halo and trifuoromethyl; R3 is hydrogen or C1–C6 alkyl 1, 2, 3 or 4; and the dotted line represents optional olefinic unsaturation; comprising hydrogenating a compound of formula III, in the presence of a nickel or cobalt catalyst at a temperature of about 5° C. to 25° C.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: February 20, 2007
    Assignee: Wyeth
    Inventors: Keun-sik Kim, Kwang-Il Kim, Ki-Byung Chai
  • Patent number: 7154001
    Abstract: A novel salt of O-desmethylvenlafaxine, O-desmethylvenlafaxine formate, is provided. Pharmaceutical compositions, dosage forms and methods of use are also provided.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: December 26, 2006
    Assignee: Wyeth
    Inventors: Anthony Francis Hadfield, Michael William Winkley
  • Patent number: 7091349
    Abstract: A process for formation of N-aryl piperazines with chiral N?-1-[benzoyl(2-pyridyl)amino]-2-propane side-chains having the structure shown in formula below, and for making intermediate compounds therefor. In this process, chirality is introduced at the piperazine ring formation step and 2-aminopyridyl substitution is incorporated via displacement. The resulting N, N? disubstituted piperazines act on the central nervous system at 5HT receptors.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: August 15, 2006
    Assignee: Wyeth
    Inventors: Gregg Brian Feigelson, Joseph Zeldis, Ivo Ladislav Jirkovsky
  • Patent number: 7030164
    Abstract: This invention relates to a highly thermally stable novel anhydrous crystalline polymorphic form of venlafaxine hydrochloride, methods for the preparation thereof, and its use.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: April 18, 2006
    Assignee: Wyeth
    Inventors: Kadum Abdul Nabi Ali, Jun Han, Yong Jai Lee
  • Patent number: 7026508
    Abstract: A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: April 11, 2006
    Assignee: Wyeth
    Inventors: Michael W. Winkley, Karen W. Sutherland
  • Patent number: 7019137
    Abstract: A process for a stereoselective preparation of novel chiral nitrogen mustard derivatives useful in synthesizing optically active 1,4-disubstituted piperazines of formula: wherein R, Ar, and Q are defined as set forth herein, and intermediate compounds therefor. The 1,4-disubstituted piperazines act as 5HT1A receptor binding agents useful in the treatment of Central Nervous System (CNS) disorders.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: March 28, 2006
    Assignee: Wyeth
    Inventors: Ivo Jirkovsky, Joseph Zeldis, Gregg Brian Feigelson
  • Patent number: 7001920
    Abstract: A novel salt of O-desmethylvenlafaxine, O-desmethylvenlafaxine formate, is provided. Pharmaceutical compositions, dosage forms and methods of use are also provided.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: February 21, 2006
    Assignee: Wyeth
    Inventors: Anthony Francis Hadfield, Michael William Winkley
  • Patent number: 6894053
    Abstract: Compounds of the formula have a long duration of action and are useful for the treatment of chronic diseases resulting from the dysfunction of the serotonergic 5-HT1A system, such as schizophrenia and other psychotic disorders such as paranoia and mano-depressive illness.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: May 17, 2005
    Assignee: Wyeth
    Inventors: Wayne E. Childers, Michael G. Kelly, Lee E. Schechter, Sharon J. Rosenzweig-Lipson
  • Patent number: 6750364
    Abstract: This invention provides compounds of the formula: wherein X is (CH2)n, O, S, SO, SO2 or CR1R2; n is 1 or 2; R1 and R2 are H, halogen, hydroxy, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or R1 and R2, taken together form cycloalkyl of 3 to 6 carbon atoms, an alkylidene of up to 6 carbon atoms or a carbonyl; R3, R4 and R5 are H or alkyl of 1 to 6 carbon atoms; Z is H, alkyl of 1 to 6 carbon atoms, alkanoyl of 1 to 6 carbon atoms or alkoxycarbonyl of 2 to 7 carbon atoms; or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods for their use in treating or preventing characterized by glutamate hypofunction, including schizophrenia, schizoaffective disorder and schizophreniform disorder, and for the treatment of cognitive deficits due to aging, stroke, Alzheimer's disease or other neurodegenerative diseases.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: June 15, 2004
    Assignee: Wyeth
    Inventors: Gary Paul Stack, John Dunlop, Alexander Alexei Greenfield, Jonathan Laird Gross
  • Patent number: 6730706
    Abstract: This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: in which A is a moiety of the formula where the dotted line represents optional unsaturation; R1 is hydrogen or alkyl; R2 is alkyl; R4 is hydrogen, alkyl, formyl, or alkanol; R5 and R6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: May 4, 2004
    Assignee: Wyeth
    Inventors: Richard L. Rudolph, G. Virginia Upton
  • Patent number: 6713626
    Abstract: A process for formation of N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane side-chains having the structure shown in formula below, and for making intermediate compounds therefor. In this process, chirality is introduced at the piperazine ring formation step and 2-aminopyridyl substitution is incorporated via displacement. The resulting N,N′ disubstituted piperazines act on the central nervous system at 5HT receptors.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: March 30, 2004
    Assignee: Wyeth
    Inventors: Gregg Brian Feigelson, Joseph Zeldis, Ivo Jirkovsky
  • Patent number: 6696450
    Abstract: Compounds of the formula have a long duration of action and are useful for the treatment of chronic diseases resulting from the dysfunction of the serotonergic 5-HT1A system, such as schizophrenia and other psychotic disorders such as paranoia and mano-depressive illness.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: February 24, 2004
    Assignee: Wyeth
    Inventors: Wayne E. Childers, Michael G. Kelly, Lee E. Schechter, Sharon J. Rosenzweig-Lipson
  • Patent number: 6689912
    Abstract: The present invention provides an efficient method of making O-desmethyl-venlafaxine.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: February 10, 2004
    Assignee: Wyeth
    Inventor: Beat T. Weber
  • Patent number: 6673838
    Abstract: A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: January 6, 2004
    Assignee: Wyeth
    Inventors: Anthony F. Hadfield, Syed M. Shah, Michael W. Winkley, Karen W. Sutherland, James A. Provost, Aeri Park, Rex A. Shipplett, Brenton W. Russell, Beat T. Weber
  • Patent number: 6627639
    Abstract: Compounds of the formula are useful in the treatment of central nervous system disorders including depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, sexual dysfunction, eating disorders and addictive disorders caused by ethanol or cocaine abuse.
    Type: Grant
    Filed: January 9, 2003
    Date of Patent: September 30, 2003
    Assignee: Wyeth
    Inventors: Gary P. Stack, Megan Tran, Byron A. Bravo
  • Patent number: 6617327
    Abstract: Compounds of the formula: are useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: September 9, 2003
    Assignee: Wyeth
    Inventors: Jonathan L. Gross, Gary P. Stack
  • Patent number: 6617334
    Abstract: Compounds of the formula: useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: September 9, 2003
    Assignee: Wyeth
    Inventors: Megan Tran, Gary P. Stack
  • Patent number: 6613913
    Abstract: Compounds of the formula: useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: September 2, 2003
    Assignee: Wyeth
    Inventors: Megan Tran, Gary P. Stack
  • Patent number: 6599915
    Abstract: Compounds of the formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: July 29, 2003
    Assignee: Wyeth
    Inventors: Megan Tran, Gary P. Stack